NUCALA is the first approved treatment to target eosinophils in patients with hypereosinophilic syndrome.
NUCALA is a prescription medicine used for the treatment of people 12 years of age and older with hypereosinophilic syndrome (HES).
Proven protection from flares*
At-home administration option available
*Flares were defined as worsening of signs and symptoms of HES or an increase in blood eosinophils (on at least 2 exams) that required increased steroids or increase/addition of other HES therapy.
†In a study, patients reported an improvement in their worst level of fatigue.
Ask your healthcare provider about NUCALA today.
Want helpful information, tools, and tips sent to your inbox?
Sign up now for more about NUCALA!
By submitting this, you certify that you are at least 18 years old.
GlaxoSmithKline (GSK) believes your privacy is important. By providing your name, address, email address, and other information, you are giving GSK and companies working with GSK permission to market or advertise to you across multiple digital and offline channels, or contact you for market research or other purposes, regarding the medical condition(s) in which you have expressed an interest, as well as other health-related information from GSK. GSK will not sell or transfer your name, address, or email address to any other party for their own marketing use. For additional information regarding how GSK handles your information, please see our privacy statement.